elovl1

ELOVL1-IN-3 is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD).

ELOVL1-IN-2, a compound known as an inhibitor of the elongation of very long chain fatty acid 1 (ELOVL1) enzyme, exhibits a weak inhibitory effect on ELOVL1 (with an IC50 of 21 μM) and demonstrates moderate potency in a primary cellular assay conducted on HEK293 C26 cells (with an IC50 of 6.7 μM) [1].

ELOVL1-IN-1 (1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide) is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD).

ELOVL6-IN-4 is a potent and selective ELOVL6 inhibitor (IC50 = 36 nM). It improves lipid metabolism and insulin sensitivity by reducing LCFA synthesis in obesity and NASH research.

Mouse Serum Albumin is the most abundant protein in plasma and can leak into the brain parenchyma when the blood-brain barrier (BBB) is compromised. It induces astrocytes to convert to the A1 phenotype, significantly increases levels of Elovl1, promotes very-long-chain fatty acids (VLSFAs) secretion, and triggers neuronal lipid apoptosis through the endoplasmic reticulum stress response pathway. Additionally, microglia activated by Mouse Serum Albumin significantly trigger tau protein phosphorylation at multiple sites (Ser202/Thr205) via the NLRP3 inflammasome pathway. It also impairs spatial learning and memory in mice. Mouse Serum Albumin is useful for studying neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD).